UCB's Global Corporate Website
Welcome to UCB in the United States
  • Healthcare Professionals
  • Patients
  • Investors
  • Apr

    23

    "The New England Journal of Medicine" Publishes Results from Two Bimekizumab Phase 3 Studies in Moderate to Severe Plaque Psoriasis

    Apr

    23

    UCB to Present 12 Abstracts on Bimekizumab at AAD VMX 2021

    UCB to Present 12 Abstracts on Bimekizumab at AAD VMX 2021 

    Feb

    23

    UCB and Microsoft Expand Collaboration to Accelerate Drug Discovery and Development

    Feb

    05

    The Lancet Publishes Two Phase 3 Studies Detailing Bimekizumab Data in Moderate to Severe Plaque Psoriasis